Resistance Analysis In The Magellan-1 Study (Part 2): Glecaprevir/Pibrentasvir Therapy In Hcv-Infected Patients Who Had Failed Prior Daa Regimens Containing Ns3/4a Protease And/Or Ns5a Inhibitors